omniture

Orchid Asia's Portfolio Company, Wuyi Pharmaceutical, Achieves a Successful IPO Listing on the Hong Kong Stock Exchange

Orchid Asia
2007-02-01 15:40 4296

Orchid Asia Led Transaction of US$18 Million in Wuyi Prior to IPO

HONG KONG, Feb. 1 /Xinhua-PRNewswire/ -- Orchid Asia, a leading private equity group focused on Chinese companies, announced that one of its portfolio companies, Wuyi International Pharmaceutical Company Limited (HKEX: 1889), has successfully achieved an IPO listing on the Main Board of Hong Kong Stock Exchange on Feb 1, 2007. Wuyi is a pharmaceutical group focused on manufacturing, marketing, and selling branded prescription with over-the-counter western pharmaceuticals and modern Chinese medicine products. Orchid Asia led the private equity transaction in investing US$18 million in Wuyi in 2006. Mr. Gabriel Li, Managing Director of Orchid Asia says, "We are very pleased to be a financial partner and strategic partner to Wuyi."

Orchid Asia has been investing in China for over 10 years and is one of the first international private equity investors in China. Throughout the past decade, Orchid Asia has invested in numerous successful companies in China including Ctrip International (listed on the Nasdaq), Eachnet (sold to eBay), Zhaopin (a leading online recruitment firm in China), Sport100 (the leading multibrand sporting goods retail chain in China), Longsheng Tea (the leading Puer tea company in China) and many other leading companies. Orchid Asia currently manages over US$250 million of capital commitments and has offices in Hong Kong, Shanghai, Guangzhou and San Francisco. The investment team consists of professionals with different backgrounds from Goldman Sachs, Carlyle, Lehman Brothers, McKinsey, GE, and others.

Contact person at Orchid Asia:

Hong Kong

Vivian Wong

Tel: +852-2115-8017

Email: vwong@orchidasia.com

Shanghai

Bei Wang

Tel: +86-21-5298-6222

Email: bwang@orchidasia.com

Source: Orchid Asia
Keywords: Food/Beverages
collection